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Case series

Do gynecologic oncology patients with severely diminished renal function
and urinary tract obstruction beneﬁt from ureteral stenting or percutaneous
nephrostomy?

T
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Objective: To assess the renal outcomes of gynecologic oncology patients who present with hydronephrosis and
acute kidney injury (AKI), have < 20% renal function on diuretic renal scintigraphy, and undergo placement of a
ureteral stent or percutaneous nephrostomy (PCN) tube.
Methods: This is a single-institution case series of gynecologic oncology patients who underwent diuretic renal
scintigraphy from January 1, 2007, to June 1, 2017. Univariate and multivariate logistic analyses were used to
assess predictors of < 20% renal function. Recovery from AKI or elevated creatinine was reported for women
with < 20% renal function who received a unilateral ureteral stent or PCN tube on the same side as their more
compromised kidney.
Results: Among 353 gynecologic oncology patients who underwent diuretic renal scintigraphy, 58 (16%) had
renal function < 20%. Mean age was 59.6 years, 17% had preexisting chronic kidney disease, and 44% had a
diagnosis of cervical cancer. Renal atrophy on computed tomography scan (aOR 18.24, 95% CI 1.21–274.92)
predicted renal function < 20%. Of 10 women with < 20% renal function who received a stent or PCN tube, 7
recovered from AKI or elevated creatinine.
Conclusions: Gynecologic oncology patients with < 20% renal function may recover from AKI after placement of
a stent or PCN tube, indicating that a diuretic renal scintigraphy cutoﬀ of < 20% renal function may be overly
conservative. Future studies are warranted to determine optimal renal function cutoﬀs for stent/PCN tube
placement in gynecologic oncology patients.

1. Introduction
Gynecologic oncology patients commonly experience urinary tract
obstruction due to tumor extension, metastatic growth, or radiation
therapy (Shingleton et al., 1969). Upon detecting such obstructions,
providers must decide whether or not to recommend placing a ureteral
stent or percutaneous nephrostomy (PCN) tube. Although such procedures might prevent acute kidney injury (AKI) and improve overall
morbidity and mortality (Lienert et al., 2009; Patel et al., 2015), they
could be futile when kidney function is too impaired.
A valuable method for assessing kidney function is diuretic renal

scintigraphy. In contrast to ultrasound and other renal imaging, this
nuclear medicine imaging study assesses both ureteral obstruction and
renal function in a single test. Renal scintigraphy measures the speed of
radiotracer clearance through the urinary tract after diuretic administration. Clearance is rapid in a non-obstructed system, but slow or entirely stagnant in an obstructed system. A further advantage of renal
scintigraphy is that it can quantify diﬀerential excretion times of the
two kidneys and calculate the percent contribution of each kidney to
the patient's total renal function.
According to the urology literature, diuretic scintigraphy revealing
≥20% kidney function is the generally accepted threshold of kidney
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categorical variables, were used to summarize demographic/clinicopathologic characteristics, stent/PCN placement, and renal outcomes. Mann-Whitney U or Student's t-test were used to analyze signiﬁcance in continuous variables, and Fisher's Exact or χ2 tests were
used for categorical variables.
Univariate and multivariate logistic regression models were used to
assess predictors of < 20% renal function. The predictors that were
signiﬁcantly diﬀerent between groups in bivariate analysis with a signiﬁcance level of 0.05 (renal atrophy on CT scan, prior pelvic/abdominal radiation, and AKI satisfying KDIGO criteria) were controlled
for in a logistic regression model. Stata 15 (Stata Statistical Software,
Release 15, College Station, TX) was used for all analyses.

salvageability (Ganatra and Loughlin, 2005; Klaipetch et al., 2013;
KDIGO, 2012; Xu et al., 2017). If kidney function is less than this cutoﬀ,
placement of a ureteral stent or PCN tube is likely to be futile. However,
no studies have assessed the validity of this cutoﬀ in a gynecologic
oncology patient population. Given that such patients' cancer treatment
options (e.g., chemotherapy, immunotherapy, radiosensitizing agents)
may depend on renal function, it is important to determine whether the
20% cutoﬀ is appropriate in this population.
To address this question, we retrospectively analyzed a case series of
gynecologic oncology patients at our institution who presented with
hydronephrosis and AKI and underwent renal scintigraphy. Speciﬁcally,
our objective was to determine the rate of recovery from kidney injury
in patients who underwent ureteral stenting or PCN on the same side as
their more compromised kidney. Additionally, because diuretic renal
scintigraphy may not be available to all gynecologic oncologists, we
sought to describe clinicodemographic predictors of < 20% renal
function.

3. Results
Our query of the nuclear medicine database yielded 420 diuretic
renal scintigraphy tests ordered by the gynecologic oncology division
between January 1, 2007, and June 1, 2017. 353 diuretic renal scintigraphy tests remained after patients with benign diagnoses were excluded and extra scans ordered within the same hospitalization or AKI
work-up were removed. Of the 353 test results, 58 (16%) revealed <
20% renal function. Of the patients with < 20% renal function, mean
age was 57.2, and most were insured, non-obese, white patients with
advanced or recurrent gynecologic malignancy, most often cervical
cancer (Table 1).
Among women with < 20% renal function, indications for diuretic
renal scintigraphy were mainly the provider's suspicion for hydronephrosis/hydroureter (84%) and/or elevated creatinine or suspected AKI
(55%). Providers ordered multiple imaging studies in tandem with
diuretic renal scintigraphy; 4 (7%) patients had a renal ultrasound and
34 (58%) had a CT scan performed within 30 days before diuretic renal
scintigraphy. Compared to patients with ≥20% renal function, those
with < 20% renal function were more likely to have renal atrophy on
CT scan (13 [19%] vs. 6 [2%], P < .01).
Predictors of < 20% renal function were evaluated in univariate
and multivariate models (Table 2). After adjusting for potential confounders, renal atrophy diagnosed on CT scan (adjusted odds ratio
[aOR] 18.24, 95% conﬁdence interval [CI] = 1.21–274.92) was associated with < 20% renal function.
We examined the subgroup of women with AKI or elevated creatinine and < 20% renal function on diuretic renal scintigraphy who
received a unilateral stent/PCN for their more compromised kidney. Of
the 10 patients in this group, 7 recovered from their AKI/elevated
creatinine and 3 did not. Among the 7 patients who recovered, median
(range) serum creatinine improved from 1.2 (1.08–1.43) mg/dl at AKI/
elevated creatinine diagnosis to 0.82 (0.75–0.90) mg/dl. Based on the
last serum creatinine measurements available at the time of data acquisition, these patients continued to have normal renal function for a
median of 13.1 (0.2–77.4) months. Table 3 describes the renal and
survival outcomes of women in this subgroup.

2. Methods
This was a single-institution retrospective case series of all gynecologic oncology patients who underwent diuretic renal scintigraphy
between January 1, 2007, and June 1, 2017. Before study initiation, all
study procedures were reviewed and approved by the Washington
University Human Research Protection Oﬃce (Institutional Review
Board project # 201708045).
Patients were identiﬁed by querying the Barnes-Jewish Hospital
(BJH) Nuclear Medicine database for inpatient and outpatient diuretic
renal scintigraphy tests ordered within the Division of Gynecologic
Oncology. We included patients with cervical, endometrial, ovarian/
fallopian/peritoneal, vaginal, or vulvar cancer, as well as gestational
trophoblastic disease, and those with a cancer of unknown but assumed
gynecologic origin. If multiple diuretic renal scintigraphy tests were
performed during the same hospitalization or AKI work-up, only the
initial scan result was included in our analysis.
Diuretic renal scintigraphy was performed at our institution as follows: Patients were ﬁrst hydrated with 500 ml of water orally and
500 ml of normal saline infused intravenously over 30 mins starting
15 mins before the procedure. Next, they were intravenously administered 7.5 mCi of Technetium Mertiatide (Tc-99 m MAG3). Patients were
then asked to void, and 2–4 mins of baseline data were acquired.
Twenty minutes after Tc-99 m MAG3 administration, 40 mg of the
diuretic furosemide was given intravenously over 1–2 mins, and data
were acquired continuously for 20 mins after furosemide administration.
AKI was deﬁned according to the Kidney Disease: Improving Global
Outcomes (KDIGO) criteria: serum creatinine increase by 0.3 mg/dl in
48 h or by 1.5-fold in 7 days (KDIGO, 2012). Other elevations in serum
creatinine noted by clinicians that did not meet criteria were captured
and classiﬁed as “elevated creatinine”. Development of chronic kidney
disease (CKD) after AKI was deﬁned according to the KDIGO criteria:
presence of kidney damage or decreased glomerular ﬁltration rate <
60 mls/min/1.73 m2 for 3 or more months (KDIGO, 2012). Failure to
salvage was deﬁned as a serum creatinine that did not return to within
25% of baseline by 3 months after the procedure or death due to AKI
(Pannu et al., 2013).
We extracted demographic and clinicopathologic data including age
at diuretic renal scintigraphy, race, insurance, tobacco use, comorbidities, primary cancer type, cancer stage, indication for diuretic renal
scintigraphy, and documented renal ﬁndings on computed tomography
(CT) scan (e.g., renal atrophy, cortical thinning, or hydronephrosis/
hydroureter) as reported by the BJH radiology department. Renal interventions (e.g., ureteral stents and/or PCN tubes) and outcomes were
captured.
Standard descriptive statistics including median and interquartile
range for continuous variables, and count and percentage for

4. Discussion
In our case series of gynecologic oncology patients with < 20%
renal function detected by diuretic renal scintigraphy, the majority of
those who underwent stent or PCN placement recovered from AKI or
elevated creatinine (7 out of 10). Although this conclusion is based on a
small sample size, it suggests that, contrary to reports in the urology
literature (Xu et al., 2017; Ortapamuk et al., 2003), 20% renal function
is not a reliable cutoﬀ for deﬁning kidney salvageability in gynecologic
oncology patients. If this conclusion is conﬁrmed in additional studies,
it has strong implications for our patient population whose treatment
options (e.g., chemotherapy, immunotherapy, radiosensitizing agents)
may depend on maintaining some degree of renal function. A prospective, multicentered study is needed to determine the optimal renal
function threshold for predicting whether or not gynecologic oncology
137

Downloaded for Anonymous User (n/a) at Washington University School of Medicine from ClinicalKey.com by Elsevier on May 22, 2019.
For personal use only. No other uses without permission. Copyright ©2019. Elsevier Inc. All rights reserved.

Gynecologic Oncology Reports 28 (2019) 136–140

B. Liang, et al.

gynecologic oncologists, we analyzed predictors of < 20% renal function in our case series of 353 gynecologic oncology patients who underwent diuretic renal scintigraphy. Renal atrophy on CT scan was a
strong, independent predictor of < 20% function on renal scintigraphy.
Thus, we conservatively recommend that gynecologic oncology patients
with suspected hydronephrosis/hydroureter and no renal atrophy detected on a CT scan can forego diuretic renal scintigraphy and proceed
directly to ureteral stenting/PCN tube placement. However, those with
renal atrophy on CT scan should undergo diuretic renal scintigraphy to
quantify their renal function. Those with renal function over 20%
should undergo ureteral stenting/PCN tube placement. Patients with
renal function < 20% should discuss with their provider the utility of
renal interventions. Such conversations should include the potential
risks of ureteral stent/PCN tube placement (e.g., recurrent infection,
tube dislocation or stent migration, and/or patient discomfort (Lienert
et al., 2009)) and their associated healthcare costs. See Fig. 1 for our
proposed algorithm for the workup for gynecologic oncology patients
with AKI or elevated creatinine and suspected hydronephrosis/hydroureter.
Strengths of this study include its unique focus on diuretic renal
scintigraphy in gynecologic oncology patients. While there is literature
involving management of upper urinary tract obstruction(s) in cancer
patients, there remain gaps in knowledge regarding the impact diuretic
renal scintigraphy can have on tailoring renal interventions and subsequent outcomes including renal function, survival, and quality of life.
Additionally, instead of using surrogate renal function measures such as
CKD or hemodialysis, we used objective renal function data from
diuretic renal scintigraphy. Important weaknesses of our study include
the small sample size drawn from a single institution and the retrospective study design, which may have been subject to selection bias.
Thus, our ﬁndings may not be generalizable. Additionally, diuretic
renal scintigraphies were ordered at the providers' discretion and were
rarely repeated after stent or PCN placement to assess recovery of renal
function. Therefore, we could only infer utility of the interventions from
patients' diagnoses of AKI or elevated creatinine. Despite these limitations, the results of our study may help gynecologic oncology patients
and providers decide whether or not to place a ureteral stent(s) or PCN
tube(s).
In conclusion, we have shown that among gynecologic oncology
patients, independent predictors of < 20% renal function include renal
atrophy observed on CT scan. Twenty percent relative renal function on
diuretic renal scintigraphy may not be an appropriate cutoﬀ for kidney
salvageability in gynecologic oncology patients, as the majority of our
patients who underwent ureteral stent/PCN tube placement had improved renal outcomes. Thus, we recommend an individualized approach for those with severely compromised renal function, including
discussion of potential risks, beneﬁts, and quality of life. Future studies
are warranted to determine optimal renal function cutoﬀs for stent/
PCN tube placement in gynecologic oncology patients.

Table 1
Demographic and clinicopathologic characteristics.
Characteristic

n (%)
Total

< 20% Renal
function

≥20% Renal
function

N = 353

N = 58

N = 295

57.2
(45.3–66.5)

60.27
(50.1–69.0)

207 (59)
103 (29)
33 (9)
10 (3)

37 (64)
14 (24)
4 (7)
3 (5)

170 (58)
89 (30)
29 (10)
7 (2)

260 (74)
84 (24)
8 (2)

45 (77)
13 (22)
0 (0)

215 (73)
71 (24)
8 (3)

33 (9)
163 (46)
156 (44)

6 (10)
23 (40)
29 (50)

27 (9)
140 (48)
127 (43)

218 (62)
67 (19)
66 (19)

31 (53)
13 (22)
13 (22)
6.5 (4.0–8.0)

187 (63)
54 (18)
53 (18)
7 (6.0–8.0)

0.18

57 (16)
181 (51)
61 (17)
160 (45)

9 (15)
30 (52)
14 (24)
33 (57)

48 (16)
151 (51)
47 (16)
127 (43)

0.89
0.94
0.13
0.05

155 (44)
89 (25)
102 (29)

28 (48)
15 (26)
15 (26)

127 (43)
74 (25)
87 (29)

7 (2)

0 (0)

7 (2)

117 (33)
206 (58)
185 (52)

14 (24)
40 (69)
31 (53)

103 (35)
166 (56)
154 (52)

120 (34)
50 (14)
32 (9)
35 (10)

24 (41)
7 (12)
5 (9)
6 (10)

96
43
27
29

Age (years)
2

BMI (kg/m )
< 30
30–39.9
40–49.9
≥50
Race
White
Black
Other
Insurance
Uninsured
Medicare/Medicaid
Private
Tobacco use
Never
Former
Current
Charleson Comorbidity
Score
Diabetes
Cardiac disease
Chronic kidney disease
Prior abdominal or pelvic
radiation
Gynecologic cancer type
Cervical cancer
Endometrial cancer
Ovarian/fallopian/
primary peritoneal
cancer
Vulvar/vaginal cancer
Stage
I-II
III-IV
Recurrent disease
Number of chemotherapy
regimens received
1st line
2nd line
3rd line
> 3rd line

P

0.07
0.44

0.41

0.54

0.24

0.59

0.08

0.86
0.80

(33)
(15)
(9)
(10)

Legend: BMI = body mass index; AKI: Acute kidney injury (deﬁned as serum
creatinine increase by 0.3 mg/dl in 48 h, or by 1.5-fold in 7 days); Cr:
Creatinine; CT: computed tomography; PCN: percutaneous nephrostomy tube.
Data are median (IQR), or n (%) unless otherwise speciﬁed. Missing values were
included in denominator of the percentages.
Table 2
Predictors of < 20% renal function as detected by diuretic renal scintigraphy.
Risk factor

Renal atrophy on CT scan
Prior abdominal or pelvic RT
AKI

Univariate

Multivariate

uOR (95% CI)

aOR (95% CI)

10.78 (3.74–31.10)
1.75 (0.99–3.08)
0.27 (0.09–0.77)

18.24 (1.21–274.92)
0.86 (0.08–8.82)
0.08 (0.001–4.90)
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Legend: CT: computed tomography; RT: radiation therapy; CKD: chronic kidney
disease, AKI: acute kidney injury (deﬁned as serum creatinine increase by
0.3 mg/dl in 48 h, or by 1.5-fold in 7 days); uOR = unadjusted odds ratio;
aOR = adjusted odds ratio; CI = conﬁdence interval.

patients will beneﬁt from a stent or PCN tube.
Because diuretic renal scintigraphy may not be available to all
138
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65

71

52

59
62

59

78
62

50

73

Recovered

Recovered

Recovered

Recovered
Recovered

Recovered

Recovered
Did not recover

Did not recover

Did not recover

Endometrial

Ovarian

Ovarian
Endometrial

Endometrial

Endometrial
Endometrial

Cervical

Cervical

Endometrial

Primary cancer

IV

IV

III
IV

IV

IV
Unknown

II

III

IV

Stage

Yes

Yes

No
No

Yes

No
Yes

No

No

No

Recurrence

0.65

1.06

0.9
Unknown

1.1

0.7
0.89

1.05

Unknown

0.81

Baseline serum
creatinine (mg/dl)

1.5

1.53

1.23
1.9

1.22

1.08
1.14

1.43

1.2

1.13

Serum creatinine at AKI /
elevated creatinine diagnosis
(mg/dl)

Legend: AKI: acute kidney injury (deﬁned as serum creatinine increase by 0.3 mg/dl in 48 hours, or by 1.5-fold in 7 days).
a
Recovery deﬁned as serum creatinine that returned within 25% of baseline by 3 months (8)
b
Serum creatinine reported at approximately 3 months post-stent or post-PCN
c
Based on availability of serum creatinine records. Normal serum creatinine deﬁned by institutional laboratory as 0.60-1.10 mg/dl

Age at AKI / elevated
creatinine diagnosis
(years)

Recovery from AKI or
elevated creatininea

1.24

1.6

0.85
1.4

0.82

0.83
0.82

0.75

0.81

0.9

Serum creatinine after
stent / PCN (mg/dl)b

n/a

n/a

13.1
n/a

14.4

28.7
0.2

77.4

1.8

1.6

Duration of sustained normal
creatinine after stent / PCN
(mo)c

Dead of
cancer
Dead of
cancer
Alive with
cancer
Alive NED
Dead of
cancer
Dead of
cancer
Alive NED
Dead of
cancer
Lost to follow
up
Dead of
cancer

Patient
Outcome

Table 3
Subgroup report on women with AKI or elevated creatinine and < 20% renal function on diuretic renal scintigraphy who received a unilateral stent/PCN for their more compromised kidney.

55.4

Unknown

≥31.4
15.1

15.4

65.4
1.7

≥96.0

2.6

2.9

Survival (mo)

B. Liang, et al.
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AKI/Elevated serum creatinine with hydronephrosis/hydroureter
Prior CT scan within 30 days available?

No

Yes
Renal atrophy present on CT scan?

No

Yes

Order diuretic renal scintigraphy

<20% relative
rela
renal function

Discuss risks and benefits with patient
of placing ureteral stent/PCN

Recommend
Ureteral Stent/PCN

Fig. 1. Algorithm for work-up of AKI or elevated creatinine in gynecologic oncology patients with suspected hydronephrosis/hydroureter.
Legend: AKI: acute kidney injury (deﬁned as serum creatinine increase by 0.3 mg/dl in 48 h, or by 1.5-fold in 7 days); CT: computed tomography; PCN: percutaneous
nephrostomy.
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